Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

Pete Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth Champney, James C. Geoghegan, Maximiliano Vásquez, Eric M. Krauland, Thomas Yockachonis, Shuangyi Bai, Bronwyn M. Gunn, Anthony Cammarata, Christopher M. Rubino, Laura M. Walker
doi: https://doi.org/10.1101/2022.10.18.22281172

Article usage

Article usage: October 2022 to November 2024

AbstractFullPdf
Oct 2022114812216
Nov 202248129256
Dec 20222514107
Jan 20231665112
Feb 202390459
Mar 2023159066
Apr 202369239
May 202341120
Jun 202335416
Jul 202319313
Aug 2023381114
Sep 202340627
Oct 202320413
Nov 202324212
Dec 202327114
Jan 202421013
Feb 202441317
Mar 20241728
Apr 202415315
May 202413310
Jun 20241214
Jul 202410111
Aug 202417313
Sep 20242746
Oct 20242668
Nov 20241229
Back to top
Posted October 19, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Pete Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth Champney, James C. Geoghegan, Maximiliano Vásquez, Eric M. Krauland, Thomas Yockachonis, Shuangyi Bai, Bronwyn M. Gunn, Anthony Cammarata, Christopher M. Rubino, Laura M. Walker
medRxiv 2022.10.18.22281172; doi: https://doi.org/10.1101/2022.10.18.22281172
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area